Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gavrilović

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neoplasma|March 25, 2000
Comparison of two non-anthracycline-containing regimens for elderly patients with diffuse large-cell non Hodgkin's lymphoma--possible pitfalls in results reporting and interpretationS Jelić, N Milanović, Z Tomasević, et al.
Srpski Arhiv Za Celokupno Lekarstvo|November 23, 2000
[Role of radiotherapy in combined therapy of soft tissue sarcoma in children and adolescents]I Golubicić, M Nikitović, J Bokun, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|March 16, 2007
The influence of steroid receptors status on disease outcome in early breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapyS Susnjar, I Kezić, Z Nesković-Konstantinović, et al.
Hematological Oncology|May 1, 1997
A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre studyS Jelić, O Frim, G Gligorijević, et al.
International Journal of Clinical Pharmacology Research|August 12, 2000
Epirubicin 150 mg/m2-cisplatin versus epirubicin 180 mg/m2-cisplatin for advanced soft tissue sarcomaS Jelić, N Babović, M Kreacić, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|March 6, 2007
Primarily tamoxifen-unresponsive, steroid receptor-positive breast cancer may respond to an aromatase inhibition: a pilot studyZ Nesković-Konstantinović, S Susnjar, D Nikolić-Vukosavljević, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patientsS Jelić, Lj Stamatović, S Vucićević, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2001
Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III studyS Jelić, L Mitrović, D Radosavljević, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 22, 1999
Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced diseaseZ Nesković-Konstantinović, D Nikolić-Vukosavljević, M Branković-Magić, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neoplasma|March 25, 2000
Comparison of two non-anthracycline-containing regimens for elderly patients with diffuse large-cell non Hodgkin's lymphoma--possible pitfalls in results reporting and interpretationS Jelić, N Milanović, Z Tomasević, et al.
Srpski Arhiv Za Celokupno Lekarstvo|November 23, 2000
[Role of radiotherapy in combined therapy of soft tissue sarcoma in children and adolescents]I Golubicić, M Nikitović, J Bokun, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|March 16, 2007
The influence of steroid receptors status on disease outcome in early breast cancer patients treated with adjuvant cyclophosphamide, methotrexate and fluorouracil chemotherapyS Susnjar, I Kezić, Z Nesković-Konstantinović, et al.
Hematological Oncology|May 1, 1997
A controversial issue: could a watch-and-wait policy for patients with non-Hodgkin's lymphoma clinical stage I or IE with no lymphoma left following diagnostic surgery be justified? Results of a single centre studyS Jelić, O Frim, G Gligorijević, et al.
International Journal of Clinical Pharmacology Research|August 12, 2000
Epirubicin 150 mg/m2-cisplatin versus epirubicin 180 mg/m2-cisplatin for advanced soft tissue sarcomaS Jelić, N Babović, M Kreacić, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|March 6, 2007
Primarily tamoxifen-unresponsive, steroid receptor-positive breast cancer may respond to an aromatase inhibition: a pilot studyZ Nesković-Konstantinović, S Susnjar, D Nikolić-Vukosavljević, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
Use of high-dose cytarabine to enhance cisplatin cytotoxicity-effects on the response and overall survival rates of advanced head and neck cancer patientsS Jelić, Lj Stamatović, S Vucićević, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2001
Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III studyS Jelić, L Mitrović, D Radosavljević, et al.
Journal of Experimental & Clinical Cancer Research : CR|December 22, 1999
Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced diseaseZ Nesković-Konstantinović, D Nikolić-Vukosavljević, M Branković-Magić, et al.
Pageof 1